Published in Br J Psychiatry on April 01, 1979
Study of Antidepressants in Parkinson's Disease (SAD-PD) | NCT00086190
Dietary Intervention for Bipolar Disorder | NCT02272010
The Role of Orexin in Human Panic Disorder | NCT02593682
Novel Neural Circuit Biomarkers of Depression Response to CCBT | NCT03096886
Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics | NCT03220776
Physical Fitness and Brain - Interventional Study (PHYSBI) | NCT03247270
rTMS Response Trajectories in Depression | NCT03348761
ED Treatment of Suicidal Patients With Ketamine Infusion | NCT03502551
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD | NCT03932773
A Single Ketamine Infusion Combined With Music for Suicidal Ideation | NCT04658420
The Impact of Spiritual Healing on Moderate Depression in Adults | NCT04766242
Neurocognitive Effects of FMT in MDD Patients With and Without IBS | NCT05174273
Can Acupuncture Treat Post-stroke Depression? (PSD2) | NCT02644161
The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med (2001) 76.04
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry (2013) 4.84
Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry (2006) 4.74
Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry (2006) 4.30
Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry (2008) 3.64
Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (2007) 3.38
Early intervention for psychosis. Cochrane Database Syst Rev (2011) 3.04
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry (2009) 3.04
An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry (2005) 3.03
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry (2012) 2.94
Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry (2015) 2.76
Randomised controlled trial of effect of intervention by psychogeriatric team on depression in frail elderly people at home. BMJ (1996) 2.69
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69
Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull (2012) 2.65
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry (2007) 2.43
CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry (2009) 2.36
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol (2009) 2.33
Differences in resting-state functional magnetic resonance imaging functional network connectivity between schizophrenia and psychotic bipolar probands and their unaffected first-degree relatives. Biol Psychiatry (2012) 2.33
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry (2011) 2.32
Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract (1997) 2.26
Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry (2006) 2.26
The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomised double blind study. BMJ (1999) 2.25
Disruption in the balance between goal-directed behavior and habit learning in obsessive-compulsive disorder. Am J Psychiatry (2011) 2.24
Preventing postoperative delirium. Dtsch Arztebl Int (2015) 2.18
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry (2009) 2.17
Whole brain resting-state analysis reveals decreased functional connectivity in major depression. Front Syst Neurosci (2010) 2.16
General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatr Scand (2013) 2.14
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
An evaluation of the effectiveness of individual and group cognitive therapy in the treatment of depressed patients in an inner city health centre. J R Coll Gen Pract (1985) 1.99
Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry (2008) 1.96
Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev (2012) 1.96
D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry (2013) 1.94
Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol (2012) 1.94
Sex Differences in the Peripheral Immune System in Patients with Depression. Front Psychiatry (2017) 1.90
Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. Br J Psychiatry (2011) 1.89
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1994) 1.85
Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry (2013) 1.85
Putting trials on trial--the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health (1997) 1.83
A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes. Diabetes Care (2013) 1.81
Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry (2011) 1.81
Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry (2005) 1.80
The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry (2010) 1.80
Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry (2013) 1.79
Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom (2009) 1.79
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology (2012) 1.77
Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. JAMA Psychiatry (2015) 1.76
Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry (2008) 1.73
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ (2014) 1.72
Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry (2010) 1.72
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Impaired cognitive flexibility and motor inhibition in unaffected first-degree relatives of patients with obsessive-compulsive disorder. Am J Psychiatry (2007) 1.71
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Disentangling the roles of approach, activation and valence in instrumental and pavlovian responding. PLoS Comput Biol (2011) 1.63
Structural Plasticity of the Hippocampus and Amygdala Induced by Electroconvulsive Therapy in Major Depression. Biol Psychiatry (2015) 1.63
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics (2010) 1.60
Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. Bipolar Disord (2009) 1.60
Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction (2012) 1.59
The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol (2006) 1.58
Event-related potential and time-frequency endophenotypes for schizophrenia and psychotic bipolar disorder. Biol Psychiatry (2014) 1.57
The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev (2009) 1.57
Antidepressants versus placebo in major depression: an overview. World Psychiatry (2015) 1.56
Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial. Psychol Med (2015) 1.55
Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol. Menopause (2013) 1.54
Psychogenic facial pain: presentation and treatment. Br Med J (Clin Res Ed) (1984) 1.53
Methylphenidate for gait impairment in Parkinson disease: a randomized clinical trial. Neurology (2011) 1.52
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
Treatment of maternal depression in a medication clinical trial and its effect on children. Am J Psychiatry (2015) 1.51
Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease: a combined MRI and SPECT study. J Neurol Neurosurg Psychiatry (2002) 1.51
A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry (2012) 1.51
Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis (2007) 1.51
Abnormal response to negative feedback in unipolar depression: evidence for a diagnosis specific impairment. J Neurol Neurosurg Psychiatry (1997) 1.50
Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry (2012) 1.48
Impact of BDNF Val66Met and 5-HTTLPR polymorphism variants on neural substrates related to sadness and executive function. Genes Brain Behav (2012) 1.48
Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study. BMC Psychiatry (2011) 1.48
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: a prospective analysis in an 8-week randomized controlled trial of acamprosate. Alcohol Clin Exp Res (2011) 1.47
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry (2012) 1.47
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. Mol Psychiatry (2015) 1.47
Diffuse microstructural abnormalities of normal-appearing white matter in late life depression: a diffusion tensor imaging study. Biol Psychiatry (2009) 1.46
A comparison of psychometric properties between internet and paper versions of two depression instruments (BDI-II and MADRS-S) administered to clinic patients. J Med Internet Res (2010) 1.46
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med (2011) 1.45
Local gyrification index in probands with psychotic disorders and their first-degree relatives. Biol Psychiatry (2013) 1.45
White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry (1999) 1.45
In search of the depressive self: extended medial prefrontal network during self-referential processing in major depression. Soc Cogn Affect Neurosci (2009) 1.45
Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA (2014) 1.44
Striatal dopamine D2/3 receptor availability in treatment resistant depression. PLoS One (2014) 1.44
Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry (2009) 1.44
The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.43
Association of functional polymorphisms from brain-derived neurotrophic factor and serotonin-related genes with depressive symptoms after a medical stressor in older adults. PLoS One (2015) 1.42
Amnestic mild cognitive impairment and incident dementia and Alzheimer's disease in geriatric depression. Int Psychogeriatr (2014) 1.41
Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci (1997) 1.41
Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev (2007) 1.40
Plasma-nortriptyline levels in endogenous depression. Lancet (1973) 3.17
5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? Arch Gen Psychiatry (1976) 3.15
A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl (1978) 2.50
A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand (1994) 2.36
Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J (1971) 2.19
Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J (1970) 2.13
A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). J Affect Disord (2001) 1.88
Routine nortriptyline levels in treatment of depression. Br Med J (1977) 1.82
Genetic control of nortriptyline kinetics in man: a study of relatives of propositi with high plasma concentrations. J Med Genet (1971) 1.66
Social functioning in depression: a review. J Clin Psychiatry (2000) 1.62
Survival analysis of suicide risk after attempted suicide. Acta Psychiatr Scand (1995) 1.55
Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry (1981) 1.52
Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine. Br J Psychiatry (1997) 1.40
["Three kinds of charity" in psychiatry. All are needed when facing human psychiatric suffering]. Lakartidningen (1998) 1.39
Recovery from depressive illness does fit an exponential model. J Clin Psychopharmacol (1996) 1.38
Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol (2000) 1.31
"Serotonin depression"--a biochemical subgroup within the affective disorders? Science (1976) 1.24
Plasma nortriptyline levels--relationship to clinical effects. Clin Pharmacol Ther (1974) 1.21
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. J Affect Disord (1997) 1.21
Suicidal behavior after severe trauma. Part 1: PTSD diagnoses, psychiatric comorbidity, and assessments of suicidal behavior. J Trauma Stress (1998) 1.15
Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet (1981) 1.14
Markers for vulnerability to psychopathology: temperament traits associated with platelet MAO activity. Acta Psychiatr Scand (1987) 1.13
Effects of fluoxetine treatment of platelet 3H-imipramine binding, 5-HT uptake and 5-HT content in major depressive disorder. J Affect Disord (1990) 1.13
A population study on irritable bowel syndrome and mental health. Scand J Gastroenterol (2000) 1.10
Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry (1980) 1.10
Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol (1997) 1.06
Suicidal behavior and cognitive flexibility: design and verbal fluency after attempted suicide. Suicide Life Threat Behav (1990) 1.04
Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clin Pharmacol Ther (1973) 1.03
Diarrhoea during treatment with clozapine: association with lymphocyte count. BMJ (1992) 1.02
A double blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand Suppl (1981) 1.01
Androgen receptor trinucleotide repeat polymorphism and personality traits. Psychiatr Genet (2001) 0.99
Pharmacological prevention of suicidal behaviour. J Affect Disord (1982) 0.97
Suicidal behavior after severe trauma. Part 2: The association between methods of torture and of suicidal ideation in posttraumatic stress disorder. J Trauma Stress (1998) 0.96
Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res (1989) 0.95
Attempted suicide predicts suicide risk in mood disorders. Acta Psychiatr Scand (1995) 0.95
Determinants of self-rating and expert rating concordance in psychiatric out-patients, using the affective subscales of the CPRS. Acta Psychiatr Scand (1996) 0.95
CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat Behav (1994) 0.95
First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol (1995) 0.95
Gingival inflammation, increased periodontal pocket depth and elevated interleukin-6 in gingival crevicular fluid of depressed women on long-term sick leave. J Periodontal Res (2007) 0.94
Homicide, suicide and CSF 5-HIAA. Acta Psychiatr Scand (1985) 0.94
The prevention of recurrent suicidal acts. Br J Clin Pharmacol (1983) 0.93
A double-blind comparison of lithium carbonate and maprotiline in the prophylaxis of the affective disorders. Br J Psychiatry (1976) 0.93
Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol (1998) 0.92
Attitudes of psychiatric nursing personnel towards patients who have attempted suicide. Acta Psychiatr Scand (1997) 0.91
Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry (1980) 0.91
The healthy control subject in psychiatric research: impulsiveness and volunteer bias. Acta Psychiatr Scand (1997) 0.90
CSF 5-HIAA and exposure to and expression of interpersonal violence in suicide attempters. J Affect Disord (2011) 0.90
CSF monoamine metabolites in melancholia. Acta Psychiatr Scand (1984) 0.90
Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand Suppl (1985) 0.89
Do some antidepressants promote suicide? Psychopharmacology (Berl) (1987) 0.89
Differential effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenaline in depression. Eur J Clin Pharmacol (1974) 0.87
Suicide risk and serotonin. Int Clin Psychopharmacol (1992) 0.87
No association between serotonin transporter gene polymorphisms and personality traits. Am J Med Genet (1999) 0.87
Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. J Affect Disord (2000) 0.87
ECNP consensus meeting March 2003 guidelines for the investigation of efficacy in substance use disorders. Eur Neuropsychopharmacol (2006) 0.87
Therapeutic effects of serotonin uptake inhibitors in depression. J Clin Psychiatry (1986) 0.86
Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatr Scand (1991) 0.86
Measurement of serum drug levels in the assessment of antidepressants. Br J Clin Pharmacol (1980) 0.85
Temperamental vulnerability in attempted suicide. Acta Psychiatr Scand (1995) 0.85
5-Hydroxyindoleacetic acid levels in attempted suicides who have killed their children. Lancet (1984) 0.85
Nurses' attitudes to attempted suicide patients. Scand J Caring Sci (1997) 0.85
Selective serotonin reuptake inhibitors in older patients. A tolerability perspective. Drugs Aging (1997) 0.85
Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiatry Res (1981) 0.85
The Karolinska Psychodynamic Profile. II. Interdisciplinary and cross-cultural reliability. Acta Psychiatr Scand (1991) 0.84
Prediction of steady-state plasma concentrations and individual dosage regimens of tricyclic antidepressants from a single test dose. Ther Drug Monit (1982) 0.84
Psychological factors in irritable bowel syndrome: a population-based study of patients, non-patients and controls. Scand J Gastroenterol (2003) 0.84
Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol (1995) 0.84
Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders. Acta Psychiatr Scand (2000) 0.84
Circadian rhythm of serotonin transport in human platelets. Psychopharmacology (Berl) (1986) 0.84
The antidepressant efficacy of zimelidine and maprotiline. Acta Psychiatr Scand Suppl (1981) 0.84
Development of a schizophrenia scale sensitive to change. Neuropharmacology (1978) 0.84
Amitriptyline plasma concentration and clinical response. Br Med J (1979) 0.83
Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol (2003) 0.83
Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters. Transl Psychiatry (2012) 0.83
Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. Int J Clin Pract (2008) 0.83
Stress and burnout in psychiatric professionals when starting to use dialectical behavioural therapy in the work with young self-harming women showing borderline personality symptoms. J Psychiatr Ment Health Nurs (2007) 0.82
Plasma levels of nortriptyline in the treatment of endogenous depression. Acta Psychiatr Scand (1973) 0.82
Skin conductance habituation and cerebrospinal fluid 5-hydroxyindoleacetic acid in suicidal patients. Arch Gen Psychiatry (1986) 0.82
Serotonergic function and suicidal behavior in personality disorders. Ann N Y Acad Sci (1986) 0.82
No association between a promoter dopamine D(4) receptor gene variant and schizophrenia. Am J Med Genet (2001) 0.82
Psychiatric care as seen by the attempted suicide patient. J Adv Nurs (2000) 0.82
Studies of CSF 5-HIAA in depression and suicidal behaviour. Adv Exp Med Biol (1981) 0.82
Monitoring tricyclic antidepressants. Ther Drug Monit (1980) 0.82
Definite and undetermined forensic diagnoses of suicide among immigrants in Sweden. Acta Psychiatr Scand (1995) 0.82
Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol (1995) 0.82
Excess tryptophan hydroxylase 17 779C allele in surviving cotwins of monozygotic twin suicide victims. Neuropsychobiology (2001) 0.82
Blood levels of melatonin, serotonin, cortisol, and prolactin in relation to the circadian rhythm of platelet serotonin uptake. Psychiatry Res (1992) 0.82
Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology. J Psychopharmacol (1993) 0.82
Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia. Schizophr Res (1999) 0.82
Neuropsychological correlates of platelet monoamine oxidase (MAO) activity in female and male subjects. Biol Psychol (1987) 0.81
Variations in CSF monoamine metabolites according to the season of birth. Neuropsychobiology (1999) 0.81
CSF monoamine metabolites of depressed patients during illness and after recovery. Acta Psychiatr Scand (1984) 0.81
Suicidal behaviour syndrome with low CSF 5-HIAA. Br Med J (1977) 0.81
Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol (2001) 0.81
Biochemical aspects of suicide. Clin Neuropharmacol (1986) 0.81
Individualization of treatment with tricyclic compounds. Med Clin North Am (1974) 0.81
Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Clin Pharmacol Ther (1977) 0.81
Lofepramine, desipramine and abnormal tests of liver function: a case report. Int Clin Psychopharmacol (1990) 0.81